Gamida Cell (NASDAQ: GMDA) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Gamida Cell to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.
This is a breakdown of current recommendations for Gamida Cell and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gamida Cell Competitors||813||2715||5973||252||2.58|
Valuation & Earnings
This table compares Gamida Cell and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Gamida Cell||N/A||-$52.93 million||-1.13|
|Gamida Cell Competitors||$934.76 million||$204.36 million||-1.15|
Gamida Cell’s rivals have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
1.7% of Gamida Cell shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Gamida Cell and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gamida Cell Competitors||-5,041.13%||-62.99%||-26.24%|
Gamida Cell beats its rivals on 7 of the 12 factors compared.
Gamida Cell Company Profile
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.